Antibacterialagent 231 (derivative 8) is an antimicrobial compound effective against multidrug-resistant Helicobacter pylori (H. pylori), with a minimum inhibitory concentration ranging from 0.25 to 0.5 μg/mL. It specifically targets the protein translocase subunit SecA and the outer membrane protein assembly factor BamD to inhibit the transport and assembly of bacterial outer membrane proteins (OMPs). Antibacterialagent 231 is suitable for studying the effects of antibiotic treatment on gut microbiome balance.